We are live on !
Find out more
Affinity Asset Advisors Portfolio holdings
AUM
$2.21B
Turnover
29.69%
1-Year Est. Return
431.26%
This Fund
S&P 500
This Quarter Est. Return
+29.83%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$2.21B
AUM Growth
+$276M
(+14%)
Cap. Flow
-$34.2M
Cap. Flow % of AUM
Cap. Flow %
-1.55%
Top 10 Holdings %
Top 10 Hldgs %
39.41%
Holding
128
New
23
Increased
32
Reduced
32
Closed
15
Avg Time Held
Equity + Options
1
year
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
0.7
years
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Tracks Biotherapeutics
TRAX
|
+$38M |
| 2 |
Roivant Sciences
ROIV
|
+$28.1M |
| 3 |
Avalo Therapeutics
AVTX
|
+$24.6M |
| 4 |
Revolution Medicines
RVMD
|
+$21.9M |
| 5 |
Insmed
INSM
|
+$20.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$55.6M |
| 2 |
Arcellx
ACLX
|
+$41.7M |
| 3 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$34.2M |
| 4 |
Terns Pharmaceuticals
TERN
|
+$29.7M |
| 5 |
Apogee Therapeutics
APGE
|
+$26.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.73% |
| 2 | Miscellaneous | 9.21% |
| 3 | Financials | 1.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Roivant Sciences
ROIV
$24.2B
| $133M | 6% |
3,750,000
+950,000
| +34% | +$28.1M |
2025 Q1
5 quarters
|
|
|
2
DELISTED
Apogee Therapeutics
APGE
| $131M | 5.92% |
987,000
-297,926
| -23% | -$26.8M |
2023 Q3
11 quarters
|
|
3
Spyre Therapeutics
SYRE
$7.47B
| $114M | 5.13% |
1,279,134
| – | – |
2023 Q2
12 quarters
|
|
4
Xenon Pharmaceuticals
XENE
$3.24B
| $96.3M | 4.35% |
1,595,000
-80,000
| -5% | -$4.44M |
2022 Q4
14 quarters
|
|
5
Erasca
ERAS
$4.68B
| $96.2M | 4.35% |
5,250,000
-100,000
| -2% | -$1.43M |
2024 Q2
8 quarters
|
|
|
6
Insmed
INSM
$21B
| $69.3M | 3.13% |
650,000
+170,000
| +35% | +$20.6M |
2024 Q2
8 quarters
|
|
7
Praxis Precision Medicines
PRAX
$6.75B
| $61.9M | 2.8% |
185,000
+15,000
| +9% | +$4.75M |
2025 Q4
2 quarters
|
|
8
Alkermes
ALKS
$6.92B
| $58.9M | 2.66% |
1,125,000
-225,000
| -17% | -$8.79M |
2023 Q3
11 quarters
|
|
9
Oruka Therapeutics
ORKA
$4.76B
| $56.2M | 2.54% |
590,000
+90,327
| +18% | +$6.02M |
2024 Q2
8 quarters
|
|
10
AnaptysBio
ANAB
$1.39B
| $55.8M | 2.52% |
826,109
-113,891
| -12% | -$6.9M |
2025 Q4
2 quarters
|
|
|
11
Avalo Therapeutics
AVTX
$604M
| $53.6M | 2.42% |
2,900,000
+1,559,160
| +116% | +$24.6M |
2024 Q1
9 quarters
|
|
12
Cytokinetics
CYTK
$8.61B
| $46.9M | 2.12% |
550,000
-150,483
| -21% | -$10.8M |
2025 Q3
3 quarters
|
|
|
13
Revolution Medicines
RVMD
$38.1B
| $46.8M | 2.12% |
250,000
+150,000
| +150% | +$21.9M |
2025 Q3
3 quarters
|
|
14
Abivax
ABVX
$7.69B
| $44M | 1.99% |
330,000
-75,000
| -19% | -$8.49M |
2025 Q1
5 quarters
|
|
|
15
First Tracks Biotherapeutics
TRAX
$1.23B
| $40.9M | 1.85% |
+2,032,012
| New | +$38M |
2026 Q2
0 quarters
|
|
16
Dianthus Therapeutics
DNTH
$4.03B
| $39M | 1.76% |
400,000
+50,000
| +14% | +$4.37M |
2025 Q3
3 quarters
|
|
17
Sutro Biopharma
STRO
$181M
| $38.9M | 1.76% |
1,172,487
+102,968
| +10% | +$3.21M |
2025 Q1
5 quarters
|
|
18
PUT
Moderna
MRNA
$87B
| $35M | 1.58% |
+500,000
| New | +$25.9M |
2026 Q2
0 quarters
|
|
19
DELISTED
Nuvalent
NUVL
| $34M | 1.54% |
275,000
-25,000
| -8% | -$2.69M |
2023 Q3
11 quarters
|
|
20
Trevi Therapeutics
TRVI
$1.69B
| $33.6M | 1.52% |
1,800,172
-200,000
| -10% | -$2.91M |
2025 Q1
5 quarters
|
|
|
21
CALL
Moderna
MRNA
$87B
| $33.3M | 1.5% |
475,000
-325,000
| -41% | -$16.8M |
2026 Q1
1 quarter
|
|
22
CALL
ARK Genomic Revolution ETF
ARKG
$1.96B
| $31.5M | 1.43% |
+750,000
| New | +$23.9M |
2026 Q2
0 quarters
|
|
23
Ovid Therapeutics
OVID
$420M
| $27.3M | 1.23% |
10,144,562
-491,756
| -5% | -$1.27M |
2025 Q1
5 quarters
|
|
24
Lexeo Therapeutics
LXEO
$217M
| $27M | 1.22% |
5,807,611
+757,400
| +15% | +$4.1M |
2025 Q1
5 quarters
|
|
25
Celldex Therapeutics
CLDX
$2.16B
| $26M | 1.18% |
700,000
+200,000
| +40% | +$6.46M |
2025 Q3
3 quarters
|
|
Similar funds
IHL
TCM
Affinity Asset Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Affinity Asset Advisors held 128 positions worth $2.21B, up 14% from $1.94B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Affinity Asset Advisors's Q2 2026 filing shows 23 new, 32 increased, 32 reduced and 15 closed positions. Its largest new stake was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M. The largest sale was Centessa Pharmaceuticals, an estimated $55.6M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Financials.
- Affinity Asset Advisors's largest Q2 2026 buy was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M.
- Affinity Asset Advisors added most to Roivant Sciences in Q2 2026, an estimated $28.1M increase.
- Affinity Asset Advisors's biggest Q2 2026 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $34.2M.
- Affinity Asset Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $55.6M.
- Affinity Asset Advisors's ten largest holdings make up 39% of its $2.21B portfolio in Q2 2026.
- Affinity Asset Advisors opened 23 new positions and closed 15 in Q2 2026.
- Affinity Asset Advisors's portfolio value rose 14% quarter-over-quarter to $2.21B.
Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.